BPIFB4 and cancer: To examine whether the LAV-BPIFB4 was also effective in reducing immunosenescence, we took advantage of the analysis of primary PBMCs isolated from GBM cancer patients including low-grade II–III (N = 6), and high-grade (N = 7) patients.